Neutralizing antibodies that merely block receptor binding are losing ground against heavily mutated SARS-CoV-2 Omicron sub-variants. A new approach now exploits a llama-derived nanobody—VHH21—that ...
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant ...
Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)
CHENGDU, China--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that it has ...
Neutralizing antibodies that merely block receptor binding are losing ground against heavily mutated SARS-CoV-2 Omicron sub-variants. A new approach now exploits a llama-derived nanobody—VHH21—that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results